D.E. Shaw & Co
ABUS icon

D.E. Shaw & Co’s Arbutus Biopharma ABUS Stock Holding History

D.E. Shaw & Co’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
381,863
+238,662
+167% +$1.05M ﹤0.01% 3272
2026
Q1 		$644K Sell
143,201
-88,562
-38% -$387K ﹤0.01% 3717
2025
Q4 		$1.11M Buy
231,763
+41,811
+22% +$188K ﹤0.01% 3463
2025
Q3 		$862K Buy
189,952
+149,252
+367% +$548K ﹤0.01% 3547
2025
Q2 		$126K Buy
+40,700
New +$135K ﹤0.01% 4107
2022
Q2 		– Sell
-19,698
Closed -$59K – 5293
2022
Q1 		$59K Sell
19,698
-3,202
-14% -$9.8K ﹤0.01% 5106
2021
Q4 		$89K Buy
+22,900
New +$89K ﹤0.01% 5089
2019
Q3 		– Sell
-19,300
Closed -$40K – 3769
2019
Q2 		$40K Sell
19,300
-28,747
-60% -$73.5K ﹤0.01% 3598
2019
Q1 		$172K Hold
48,047
– – ﹤0.01% 3423
2018
Q4 		$184K Sell
48,047
-12,509
-21% -$61.6K ﹤0.01% 3564
2018
Q3 		$572K Sell
60,556
-409,952
-87% -$4.07M ﹤0.01% 3030
2018
Q2 		$3.44M Sell
470,508
-239,954
-34% -$1.43M ﹤0.01% 1807
2018
Q1 		$3.55M Sell
710,462
-495,663
-41% -$2.62M ﹤0.01% 1643
2017
Q4 		$6.09M Sell
1,206,125
-547,980
-31% -$3.21M 0.01% 1358
2017
Q3 		$10.9M Buy
1,754,105
+19,576
+1% +$83.7K 0.02% 895
2017
Q2 		$6.24M Sell
1,734,529
-12,573
-0.7% -$43.3K 0.01% 1184
2017
Q1 		$5.68M Buy
1,747,102
+12,499
+0.7% +$34.7K 0.01% 1205
2016
Q4 		$4.25M Buy
1,734,603
+13,622
+0.8% +$39.6K 0.01% 1455
2016
Q3 		$5.92M Sell
1,720,981
-20,914
-1% -$81.7K 0.01% 1189
2016
Q2 		$6.06M Buy
1,741,895
+30,326
+2% +$128K 0.01% 1165
2016
Q1 		$7.07M Sell
1,711,569
-159,891
-9% -$571K 0.01% 1057
2015
Q4 		$8.33M Buy
1,871,460
+14,384
+0.8% +$78.8K 0.01% 1056
2015
Q3 		$11.3M Sell
1,857,076
-157,536
-8% -$1.4M 0.02% 894
2015
Q2 		$23.9M Buy
2,014,612
+332,712
+20% +$5.06M 0.04% 567
2015
Q1 		$29.4M Buy
1,681,900
+1,625,221
+2,867% +$33.3M 0.05% 468
2014
Q4 		$859K Buy
56,679
+45,773
+420% +$790K ﹤0.01% 2946
2014
Q3 		$231K Buy
+10,906
New +$178K ﹤0.01% 3822

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co's ABUS Position: Q2 2026 in Review

D.E. Shaw & Co increased its Arbutus Biopharma (ABUS) stake by 167% in Q2 2026, buying an estimated $1.05M and bringing the position to 381,863 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

D.E. Shaw & Co first reported a position in ABUS in Q3 2014 and has held it in 27 quarters since. The position peaked at $29.4M in Q1 2015. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • D.E. Shaw & Co held 381,863 shares of Arbutus Biopharma worth $1.83M as of Q2 2026.
  • D.E. Shaw & Co bought 238,662 Arbutus Biopharma shares in Q2 2026, an estimated $1.05M.
  • Arbutus Biopharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3272 holding.
  • D.E. Shaw & Co first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 27 quarters since.
  • D.E. Shaw & Co's Arbutus Biopharma position peaked at $29.4M in Q1 2015.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.